SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus (Q37872125)

24 August 2017

1 reference

title

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus (English)

1 reference

24 August 2017

0 references

Raktim Kumar Ghosh

1

1 reference

24 August 2017

Samhati Mondal Ghosh

series ordinal

2

1 reference

24 August 2017

Shalini Chawla

series ordinal

3

1 reference

24 August 2017

Sarfaraz Abdeli Jasdanwala

series ordinal

4

1 reference

24 August 2017

4 May 2011

1 reference

The Journal of Clinical Pharmacology

24 August 2017

1 reference

24 August 2017

52

1 reference

24 August 2017

4

1 reference

24 August 2017

457-463

1 reference

Recent and emerging anti-diabetes targets

24 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Current therapies and emerging targets for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Thiazolidinediones, insulin resistance and obesity: Finding a balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Emerging therapies for metabolic diseases--the focus is on diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

The sodium/glucose cotransport family SLC5

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011400604

21 January 2018

Identifiers

DOI

10.1177/0091270011400604

1 reference

24 August 2017

1 reference